Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over 18 years of age
- People of any gender or ethnicity
- People who are able and willing to attend ALTENS therapy sessions over a 12-week period
- People who have previously received radiation treatment to the head and neck area at a dose greater than 50 Gy
- People who experience dry mouth as a symptom
- People with no signs of active cancer in the head and neck area
- People who are at least 3 months past their initial curative treatment, with no signs of active disease shown on standard follow-up scans
Who may not be able to join:
- People under 18 years of age
- People who are unable to attend ALTENS therapy sessions
- People who are unable to complete quality-of-life questionnaires
- People who are currently receiving, or plan to receive, chemotherapy and radiation therapy at the same time
- People with unstable angina (a type of chest pain condition)
- People with unstable heart disease who have been hospitalised in the last 6 months
- People who have a pacemaker, implanted heart device (ICD), or any other electronic implanted device that could be affected by the therapy
- People who have had a heart attack in the last 6 months
- People who have had a significant irregular heartbeat causing symptoms in the last 6 months
- People with severe chronic lung disease (COPD) who have been hospitalised due to a flare-up within the last 6 months
- People who are pregnant or who think they may be pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (585) 273-4839
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients with a mean parotid dose > 25 Gy have an improvement on the XeQoL questionnaire that is significantly different than those with a mean dose < 25 Gy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.